

OncoTarget® is cutting edge NGS Panel designed to identify targeted mutations in Bladder, Breast, Colon, GI, Lung, Melanoma, Ovary, Prostate, Rectal, and Thyroid.

OncoTarget® Test Outcomes

Genomic Alteration –


Easy to interpret - Tier classifications and appropriate therapeutic recommendations.

Note: PD-L1 expression on tissue is an add-on option if requested


Benefits of OncoTarget®

- Affordable genomic test with deep coverage of disease-specific guideline recommended genes.
- Easily comprehensible results.
- Improves accessibility of genomic tests.
- OncoTarget® is also **customizable** with ability to select **upto 20 genes** for each cancer type.

Types of alterations covered in OncoTarget®




How OncoTarget® tailors relevant information for patients?



Accelerate treatment decisions with OncoTarget®


- **Detect:** Clinically actionable guideline specific genomic mutations
- **Identify:** Novel genomic targets and biomarkers
- **Predict:** Disease prognosis and treatment responses

Key Actionable Genes Include:




Lung

EGFR, ALK, HRAS, NRAS, KRAS, BRAF, TERT, ROS1, MET, RET, NTRK1/2/3, ERBB2 (HER2), PIK3CA




Melanoma

BRAF, CD274, CDKN2A, NRAS, NTRK1, NTRK2, NTRK3, ROS1, MSI*




Prostate

BRCA1, BRCA2, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51D, MSI*




Ovary

BRAF, BRCA1, BRCA2, MLH1, MSH2, MSH6, MTOR, NTRK1, NTRK2, NTRK3, RET, MSI*




Thyroid

ALK, BRAF, MLH1, MSH2, MSH6, NTRK1, NTRK2, NTRK3, PMS2, MSI*




Breast

BRCA1, BRCA2, ERBB2 (HER2), PIK3CA, MLH1, MSH6, PMS2, NTRK1/2/3, ESR1, BRAF, PALB2, RET




Bladder

MLH1, CDKN2A, ERBB2(HER2), FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, PIK3CA, MSI, MSH6, NTRK1/2/3, PMS2, TP53, TSC1



Gastrointestinal

KIT, STK11, MLH1, MSH2, MSH6, PMS2, ALK, HRAS, ERBB2 (HER2), NRAS, KRAS, BRAF, ROS1, MET, RET, NTRK1/2/3, PDGFRA, NF1, FGFR fusions



Colorectal

BRAF, KRAS, NRAS, ERBB2 (HER2), MLH1, MSH2, MSH6, PMS2, NTRK1/2/3, TP53, EPCAM, PIK3CA, PTEN, RET, AKT1, BRAF, HRAS, MET, SMAD4

OncoTarget® performance characteristics

Specimen	OncoTarget® (LBx or TBx)
Sample Type	Plasma cDNA (BD Pax-Gene Tube) + 1 tube of 8.5 ml Peripheral Whole Blood [Note: ~8-10 days of washout period required if patient under therapy e.g., Chemotherapy, Radiation, Immunotherapy, etc.] OR 1 FFPE tissue block with 20-30 % tumor content. (Note: Not more than 3-4 months old)
Sample Collection	Peripheral blood using butterfly needles/ 22 gauge syringe
Sample volume/quantity	2 PAXGene tube + 1K2 EDTA peripheral whole blood OR 1 FFPE block with 20-30% tumor content
cfDNA/DNA input amount	> 1ng
Sequencing platform	Illumina
Read Length	2 x 150bp
Mean Sequencing Depth	2000x/10000x
Sequencing Chemistry	Hybrid capture
Indications	Clinically diagnosed OncoTarget® associated cancers
Analysis and Reporting	iCare™- AI based analysis platform with active reporting options

Precision Targeted
Genomic Insight

Your Path to
Personalized Care